Comment from Amgen Inc.
AnonymousOpposeBusiness
Summary: Amgen, the parent company of ChemoCentryx, opposes the FDA's proposal to withdraw approval of TAVNEOS (avacopan). They argue that the drug's benefits outweigh its risks for patients with rare diseases and request a hearing to present additional data and studies.
Please see attached on behalf of ChemoCentryx, Inc. and its parent company, Amgen Inc.